Fra-1 governs cell migration via modulation of CD44 expression in human mesotheliomas
© Ramos-Nino et al; licensee BioMed Central Ltd. 2007
Received: 09 July 2007
Accepted: 21 December 2007
Published: 21 December 2007
Silencing of Fra-1, a component of the dimeric transcription factor, activator protein-1 (AP-1), inhibits mRNA expression of c-met and cd44 in rat mesothelioma cells and is causally linked to maintenance of the transformed phenotype. However, the mechanisms of Fra-1 regulation and Fra-1 regulated gene expression in human malignant mesothelioma (MM) are unclear. We first show in a panel of human MM cells that Fra-1 mRNA expression in MM is complex and regulated by extracellular signal-regulated kinase (ERK1, ERK2), Src, and phosphatidyl-inositol-3-kinase (PI3K) pathways in a tumor-specific fashion. Cell lines with PI3K-dependent Fra-1 expression were SV40 positive and expressed the lowest basal Fra-1 levels. Levels of Fra-1 expression correlated with amounts of CD44 expression that were greater in simian virus 40 negative (SV40-) MM cells. Using dominant negative (dn), short hairpin (sh) and small interference (si) RNA constructs, we next demonstrate that expression of CD44, the principal hyaluronic receptor in MMs, correlates with Fra-expression in both simian virus 40 positive (SV40+) and SV40- MMs. Moreover, both Fra-1 and CD44 expression are linked to cell migration in SV40- MM cells. Lastly, in contrast to normal lung tissue, tissue microarrays revealed that Fra-1 was expressed in 33 of 34 human MMs, and that all CD44+ tumors were SV40-. These results suggest that Fra-1 is associated with cell migration in human MMs and that Fra-1 modulation of CD44 may govern migration of selected MMs.
Malignant mesothelioma (MM) is an insidious tumor associated historically with occupational exposure to asbestos [1, 2]. Recently, infection by simian virus 40 (SV40) has been implicated as a contributory factor in the development of MMs [3, 4] but these findings are controversial [5–7]. The average survival of patients is less than 1 year after initial diagnosis of MM, and no successful treatment options exist for the majority of patients [1, 3]. These pleomorphic tumors are unique in that they have a long latency period (average of 30+ years) and various pathologies (epithelial, sarcomatous and mixed) that complicate their diagnosis and may govern their prognosis [1, 3].
Although the mechanisms of development of MM are obscure, the initiation of signaling events after interaction of mesothelial cells with asbestos fibers or infection by SV40 may result in transactivation of genes governing cell proliferation and other properties of neoplastic cells [2, 8, 9]. The transcription factor, activator protein-1 (AP-1) consists of members of the Jun (c-Jun, JunD, JunB) and Fos (c-Fos, FosB, Fra-1, Fra-2) family of early response protooncogenes [10, 11] and is a major target of asbestos-induced cell signaling via activation of mitogen activated protein kinases (MAPK) [12, 13].
In comparison to other Jun and Fos family members, increases in Fra-1 expression by asbestos are protracted in rodent lung epithelial  and pleural mesothelial cells and are critical in maintenance of the malignant phenotype of rat MMs . Moreover, cd44, which encodes the principal hyaluronic acid receptor in a variety of cell types, is a fra-1 regulated gene in rat MMs .
CD44 is a type I transmembrane glycoprotein (85–200 kDa) and functions as the major cellular adhesion molecule for hyaluronic acid (HA), a component of the extracellular matrix (ECM). CD44 is expressed in most human cell types and is implicated in a wide variety of physiological and pathological processes, including lymphocyte homing and activation, wound healing, cell migration, tumor cell growth, metastasis [17, 18] and chemoresistance . The CD44 gene consists of at least 19 exons, of which 12 can be alternatively spliced , and this differential gene expression through alternative splicing is important to various physiological and pathological conditions . The most common isoform expressed in a variety of cell types is CD44s (standard). The distribution of the CD44 variants is usually restricted, and some variants are only expressed in certain tumor cells where their expression can confer metastatic properties .
The CD44 hyaluronic acid receptor is upregulated in human MMs , and increased hyaluronic acid in pleural fluid and serum is used both as a diagnostic and prognostic indicator of MM [23–27]. In a previous study, it was found that MM cell lines that expressed the highest amount of CD44 receptor showed increased proliferation and haptotactic migration when stimulated with low molecular weight hyaluronic acid . Furthermore, the use of a monoclonal antibody against CD44 inhibited proliferation by 12–40% and migration by 10–35% in the MM cell lines that were studied . The goal of studies here was to elucidate cell signaling pathways leading to transactivation of CD44 by Fra-1 and their functional ramifications on migration of both SV40+ and SV40- human MM cells. We first established that Fra-1 expression is inducible by serum and is heterogeneous in different MM cells when modulated by inhibitors of the P13K, Src or ERK1/2 pathways. Levels of Fra-1 correlated with CD44 protein levels that were higher in SV40- MMs. The functional significance of Fra- 1- dependent CD44 expression was determined in high CD44-expressing SV40- MM cells using small hairpin (sh) RNA interference constructs. These experiments showed that inhibition of Fra-1 or CD44 significantly curtailed MM cell migration. More importantly, Fra-1 overexpression was observed in 33 of 34 human MMs in tissue arrays and all CD44+ tumors were SV40-.
Inhibition of PI3K, Src or the ERK1/2 pathway diminishes Fra-1 expression, transactivation and protein levels in human MM cells in a tumor-specific manner
Levels of Fra-1 and CD44 expression are greater in SV40- human MM cells
Levels of Fra-1 and modulation of its upstream regulators are associated with CD44 expression levels
shFra-1 and shCD44 constructs inhibit motility of MM cells
shFra-1 constructs reduce hyaluronic acid uptake of MM cells
Tissue arrays demonstrate that Fra-1 is overexpressed in the majority of MMs
Tissue arrays demonstrate that SV40 T-antigen expression in MM cells correlates with CD44- status
Cell localization of Fra-1 compared to SV40 and CD44 status in human MMs.
The AP-1 family member, Fra-1, is up-regulated in several tumors, including stomach , esophageal , squamous cell carcinomas , thyroid [33, 34], and breast tumors . Although Fra-1 plays an important role in cell transformation and is upregulated by cigarette smoke, mitogens and phorbol ester tumor promoters [33–43], little is known about how this important protein is regulated in human tumors. Moreover, the functional ramifications of its expression and its mechanisms of action on individual tumor types are unclear.
Fra-1 expression and its activation by the ERK1/2 pathway have been well documented in several systems including rat MM cells . More recently, gene profiling studies revealed that Fra-1 was an AKT-inducible gene in prostate cancer cells and vascular smooth muscle cells [36, 39] and was a PI3K-dependent gene in human bronchial epithelial cells  and MM cells . Here we present evidence that Fra-1 mRNA expression is complex in human MMs, involving activation of the ERK1/2, PI3K, and Src pathways in a tumor cell-specific manner. In contrast, levels of Fra-1 in MMs were not modified by pre-addition of an inhibitor of EGFR phosphorylation (AG1478) although it is known that EGFR phosphorylation leads to ERK1/2 activation in rodent mesothelial  and alveolar epithelial cells . Moreover, both matrix metalloproteinase/EGFR/MAPK  and PI3K regulated AKT independent signaling pathways regulate Fra-1 induction by cigarette smoke .
We previously reported that increases in Fra-1 expression in rat mesotheliomas were causally linked to genes governing cell motility and invasion (cd44 and met) . Other investigators also have reported that AP-1 mediated invasion of transformed fibroblasts requires increased expression of CD44 . We hypothesize that the increased expression of Fra-1 in the AP-1 complex causes the activation of target genes that influence malignancy and invasion of human MMs. Here we present evidence that Fra-1 activation is through multiple survival pathways and that its expression governs human mesothelioma cell migration partially via indirect modulation of CD44 expression.
In human MM cell lines and tumors, the degree of constitutive Fra-1 expression is tumor line-dependent. The localization of Fra-1 in all tumors was primarily nuclear, but some cytoplasmic localization could be observed in CD44- tumors. Although the nuclear localization of any transcription factor is of critical importance for its function in downstream gene regulation, the cytoplasmic localization of Fra-1 could also have some impact in its function. Simultaneous nuclear and cytoplasmic localization of Fra-1 has been reported in breast malignancies , although its functional significance was unexplored.
We show here that low basal Fra-1 and CD44 levels correlated with SV40 positivity in MM cell lines and could be upregulated upon stimulation with serum. Previous studies have demonstrated that SV40 large T antigen can activate the PI3K pathway in different cell types [48, 49], and, in line with these observations, we have shown that SV40+ MM cells have higher AKT activity [50, 51]. Moreover, SV40+ MMs were more susceptible to killing when the PI3K pathway was inhibited. These studies suggest that SV40 positivity of MMs may render a survival advantage. However, CD44 does not contribute to the migration of SV40+ MM cells which may depend upon multiple mechanisms including voltage-gated sodium channels , expression of the EphA2 receptor , MAPK-regulated MMPs [54–56], and integrin or ECM composition and synthesis .
The presence and role of SV40 in human tumors is still very controversial, but SV40 T-antigen or DNA has been found in human MMs [5, 58]. Results here suggest that SV40 is a contributor to the heterogeneity of migration responses found in human MMs.
The role of other Fra-1-dependent genes and signaling pathways should be explored in prevention and therapy of MMs of both SV40+ and SV40- MMs.
Human mesothelioma (MM) cell lines
Human pleural mesothelioma cell lines were isolated from patients at autopsy (from Dr. Michele Carbone, University of Hawaii, Honolulu, HI (MM3, MM4, MM7), and Dr. Luciano Mutti (Maugeri Foundation, Pavia, Italy) (MM1, MM6), or from surgical debulking of MMs from Dr. Harvey Pass (New York University, NY, NY) (MM2). The cell line MM5 (#CRL-2081) was obtained from the ATCC (Manassas, Virginia). All MM cell lines were tested for the mRNA expression of large and small T/t-antigen by PCR before each experiment. The MM1, MM2, MM5, and MM6 lines were negative for SV40 large T-antigen (SV40-), whereas MM3, MM4 and MM7 were SV40+. Cells were maintained in frozen stocks and propagated in DMEM/F12 medium (GIBCO BRL, NY) containing 10% fetal bovine serum (FBS), hydrocortisone (100 ng/ml), insulin (2.5 μg/ml), transferrin (2.5 μg/ml), and selenium (2.5 ng/ml) (Sigma, St Louis, MO).
Small molecule inhibitors and chemicals
Stock solutions of all inhibitors were diluted in dimethyl sulfoxide (DMSO) and used at effective nontoxic concentrations as reported previously: The MEK1/2 inhibitor, PD98059, at 30 μM ; the EGFR inhibitor, AG1478, at 10 μM ; the PI3K inhibitor, LY294002, at 10 and 20 μM ; and the Src inhibitor, PP2, at 10 μM . All chemicals were obtained from Calbiochem (La Jolla, CA). Control groups of cells also received DMSO (0.1%) in medium.
Western blots analyses
Nearly confluent MM cells were washed 3 × with cold phosphate-buffered saline (PBS), scraped from culture plates, and collected by centrifugation at 14,000 rpm for 1 min. The pellet was resuspended in lysis buffer [20 mM Tris (pH 7.4), 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM β-glycerophosphate, 1 mM Na3VO4, 2 mM pyrophosphate, 1 mM PMSF, 10 μg/ml leupeptin, 1 mM DTT, 10 mM NaF, 1% aprotinin], incubated at 4°C for 15 min, and centrifuged at 14,000 rpm for 20 min. Protein concentrations were determined using a Bio-Rad assay (Bio-Rad, Hercules, CA). Twenty μg of protein in sample buffer [62.5 mM Tris-HCl (pH 6.8), 2% sodium dodecyl sulfate (SDS), 10% glycerol, 50 mM dithiothreitol, 0.1% w/v bromophenol blue] was resolved by electrophoresis in 10% SDS-polyacrylamide gels, and transferred to nitrocellulose using a semi-dry transfer apparatus (Ellard Instrumentation, Ltd., Seattle, WA). Blots were incubated in blocking buffer [Tris-buffered saline (TBS) containing 5% nonfat dry milk plus 0.1% Tween-20 (Sigma)] for 1 h, washed 3 × for 5 min each in TBS/0.1% Tween-20, and incubated at 4°C overnight with antibodies specific to CD44 and Fra-1 at a dilution of 1:500 (Santa Cruz Biotechnology Inc., Santa Cruz, CA). Blots were then washed 3 × with TBS/0.1% Tween-20 and incubated with a specific peroxidase-conjugated secondary antibody at a dilution of 1:5,000 (Amersham Pharmacia Biotech, Piscataway, NJ) for 1 h. After washing blots 3 × in TBS/0.1% Tween-20, protein bands were visualized with the LumiGlo enhanced chemiluminescence detection system (Kirkgaard and Perry Laboratories, Gaithersburg, MD) and quantitated by densitometry . Blots were reprobed with an antibody to α-Tubulin in a dilution 1:1,000 (Santa Cruz Biotechnology, Santa Cruz, CA) or β-Actin at a dilution of 1:5,000 (Abcam Inc, Cambridge, MA) to validate equal loading between lanes .
Cells were transiently co-transfected with 2 μg reporter plasmid, human Fra-1 promoter-luciferase (-861/+32) (kindly obtained from Dr Sekhar Reddy, Johns Hopkins University, Baltimore, MD) and renilla (0.5 μg) using lipofectamine 2000 (Invitrogen, Life Technologies, Grand Island, NY) according to the manufacturer's instructions. After 24 h, cells were switched to 0.5% FBS-containing medium before exposure to different agents. After exposure to LY294002 (20 μM) or DMSO as a control diluent (with samples N = 3), total cell extracts were prepared and assayed for luciferase and renilla activity (Luciferase Assay System; Promega Corp., Madison, WI) using a luminometer (Berthold Technologies, Lumat, Germany). Luciferase activity was expressed as the ratio of luciferase to renilla and then normalized with respect to the control.
Electrophoretic mobility shift assays (EMSA)
Electrophoretic gel mobility shift assays (EMSA) were used to assess binding of AP-1 to DNA and composition of AP-1 complexes. Nuclear extracts were prepared and analyzed as described by Ramos et al.. The amount of protein in each sample was determined using the Bio-Rad protein assay (Bio-Rad, Hercules, CA). For supershift assays, nuclear extracts were incubated with antibodies to Fra-1 (Santa Cruz, CA) for 15 min at room temperature prior to addition of labeled oligonucleotide. Gels were quantitated using a Bio-Rad phosphoimager (Bio-Rad, Hercules, CA).
Chromatin immunoprecipitation (ChIP) assays
MM cells (5 × 107) were starved in medium containing 0.5% FBS overnight and then stimulated with 10% FBS for 3 h. ChIP was performed using a commercially available kit (AVIVA Systems biology, San Diego, CA). Briefly, chromatin was crosslinked by adding formaldehyde (1%) to culture medium for 15 min and sonicated. A fraction of the soluble chromatin was saved for measurement of total chromatin input. The soluble chromatin was precleared and then was immunoprecipitated with 3 μg of Fra-1 antibodies (Santa Cruz Biotechnologies), 18 h at 4°C, and the immune complexes were absorbed with protein A/G beads. Immunoprecipitated purified DNA was analyzed by semi-quantitative PCR and densitometry was used to quantify the PCR results. The CD44 promoter was analyzed using primers: forward 5'-tttacagcctcagcagagc-3' and reverse 5'-ggaagttggctgcagttttt-3", which yield a 184-bp DNA product.
Real Time Quantitative PCR
Primers and probes (FAM/TAMRA labeled) for Real time Q-PCR assays.
Primers and Probes
Transfection techniques and constructs
RK7-Fra-1Δzip, a dominant negative Fra-1 (dnFra-1) construct with deletion of the leucine zipper responsible for the dimerization function of Fra-1, was obtained from Dr. M. Busslinger (Research Institute of Molecular Pathology, Vienna, Austria) and cloned into pcDNA3 (InVitrogen, San Diego, CA) before transfection using electroporation. Briefly, cells were grown to 80–90% confluence, trypsinized, counted, and resuspended at 3 × 106 cells/ml at room temperature. An aliquot of the cell suspension (400 μl) was mixed with 10 μg of plasmid DNA (expression or control plasmids) and electroporated at 280 V and 850 μF capacitance. Cells were immediately plated in fresh growth medium in 35 mm culture dishes and allowed to recover overnight. Following an overnight recovery, cells were selected for neomycin resistance using 200 μg/ml G418 (Sigma). Colonies surviving G418 selection were expanded and tested for the presence of Fra-1 as an indicator of plasmid activity. The Fra-1 and CD44 RNA interference (RNAi) duplexes were constructed from sequence information about mature mRNA extracted from the NIH genetic sequence database (GenBank®). The open frame region from the cDNA sequence of exon 2 of the Fra-1 gene, and exon 5 (common exon to all splice forms) of the CD44 gene. The siRNA sequences targeting Fra-1 corresponded to the 230–250 coding region relative to the first nucleotide of the start codon, and the sequence targeting CD44, corresponded to the 480–500 coding region relative to the first nucleotide of the start codon. The sequences were BLAST-searched (NCBI database) against EST libraries to ensure the specificity of the siRNA molecule. The designed oligonucleotides were inserted and structured as follows: BamHI-sense-loop-antisense-HindIII small hairpin RNA (shRNA) in the expression vector pSilencer 3.1 H1-neo siRNA (Ambion). The vector was transfected using Lipofectamine 2000 (Invitrogen) as recommended by the manufacturer. Cells were immediately plated in fresh growth medium in 35 mm culture dishes and allowed to recover overnight. Following an overnight recovery, cells were selected for neomycin resistance using 200 μg/ml G418 (Sigma St. Louis, MO). Colonies surviving G418 selection were expanded and tested for the presence of mRNA levels of Fra-1 and CD44 using 27 cycles of PCR at an annealing temperature of 57°C (Fra- 1 forward primer: agtcaggagctgcagtgga and reverse primer: ctgctgctactcttgcgatg; CD44 forward primer: aagacatctaccccagcaac and reverse primer: ccaagatgatcagccattctgg and GAPDH control forward primer: cgggaagcttgtgatcaatgg and reverse primer: ggcagtgatggcatggactg).
Cell motility assay
Twelve-well plastic plates were coated with 1–2 mm isotonically prepared type I/II collagen (Vitrogen 100. Cohesion, PaloAlto, CA) as recommended by the manufacturer, incubated at 37°C for 1 h to promote gelation, and dried in a laminar flow hood overnight. The dry film was then rinsed with sterile water to remove salts and re-hydrate the film. Cells were seeded on the collagen-coated plates with complete medium as described above, and grown until confluent. Cells were maintained in serumless medium for 48 h before each assay. Control experiments were performed where cell replication was inhibited 2 h prior to treatment with 1 μg/ml aphidicolin to account for cell movement due to cell growth. After treatment for 1 h with the different inhibitors, a wound was made on the coverslips using a 100 μl plastic tip, and a small 2-mm2 area was marked with a template for further observations using phase contrast microscopy (Olympus M081, Olympus Industrial America Inc.) After complete medium was added, the migration of cells then was examined at 8, 24, and 48 h. A final count of cells that moved into the marked area that exhibited a spreading morphology (thin, long axis) was performed at 24 h, and the relative cell motility was estimated as a % of the area covered by cells over the total area.
Hyaluronic acid uptake assay
Receptor-mediated internalization of BODIPY FL dye-labeled hyaluronic acid derivative was assayed as described previously . Briefly, cells were grown in glass coverslips, and then treated with BODIPY FL HA conjugate probe (Molecular Probes, Carlsbad, CA, now Invitrogen) at 100 μg/ml for 2 h. Unbound probe was removed by washing 3 × with phosphate buffered saline (PBS). Cells were fixed with 3% paraformaldehyde for 10 min at room temperature and washed again with PBS. Then the slides were nuclear counterstained with DAPI (5 μg/ml solution) (Molecular Probes, Carlsbad, CA). Coverslips were mounted onto slides with AquaPolyMount (Polysciences Inc., Warrington, PA). The sections were viewed with a BioRad MRC 1024 Confocal Scanning Laser Microscope (BioRad, Hercules, CA), and images were captured in sequential mode using Lasersharp 2000 software.
Human MM tissue arrays consisting of 2 mm representative areas of resected MM (N = 34) and normal lung tissue (N = 2) were obtained from Dr. Pass (New York University, NY, NY). Arrays and other samples containing formalin-fixed, paraffin-embedded samples were deparaffinized in xylene (2 × 15 min) and rehydrated in a graded ethanol series (95% to 50%). Slides were rinsed in water and placed in 1 × DAKO antigen retrieval solution (DakoCytomation, Glustrup, Denmark) and incubated at 95–99°C for 40 min. Slides then were washed 2 × for 5 min in 1 × PBS, and blocked with 50 μl of normal goat serum (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) diluted in 950 μl PBS for 30 min in a humidified chamber at room temperature. A cocktail of polyclonal anti-rabbit Fra-1 antibody (R-20) (Santa Cruz Biotechnology Inc., Santa Cruz CA) diluted 1:100 and anti-mouse phosphorylated-p42/p44 (p-ERK1/2) (Cell Signaling Technology, Beverly, MA) diluted 1:100 in 1% BSA in PBS was applied to each slide and incubated overnight in a humidified chamber at 4°C. Sections then were washed in PBS and incubated for 30 min at room temperature in the dark with a secondary antibody cocktail [AlexaFluor goat anti-rabbit 568 (red), and AlexaFluor goat anti-mouse 647 (far red = blue) (Molecular Probes, Eugene, OR)]. Following a final wash in PBS, sections were counter-stained with SYTOX green (1:1,000 in PBS) or DAPI (5 μg/ml) (Molecular Probes, Eugene, OR), to detect nuclei, washed 1× in PBS, and mounted on glass slides using AquaPoly/Mount (Polysciences Inc., Warrington, PA). A negative control tissue omitting incubation with the primary antibody was included in each run.
A second set of arrays were deparaffinized as described above and double-stained with antibodies to SV40 T-antigen (Pab 101)(Santa Cruz Biotechnology Inc., Santa Cruz CA) and CD44 (Zymed/Invitrogen, Carlsbad, CA) as described previously . The sections were viewed with a BioRad MRC 1024 Confocal Scanning Laser Microscope (BioRad, Hercules, CA), and images were captured in sequential mode using Lasersharp 2000 software. In addition to qualitative observations for staining, localization and extent, slides were semi-quantitatively scored for intensity on a scale of 0 to 3 using a blind coding system (data not shown).
In all experiments, duplicate or triplicate determinations were conducted for each group per time point. Experiments were performed in duplicate. Results were evaluated by one-way analysis of variance using the Student-Newman-Keuls procedure for adjustment of multiple pairwise comparisons between treatment groups. Differences with p values ≤ .05 were considered statistically significant.
Transcription factor, Activator protein-1
Extracellular signal-regulated kinase
Simian virus 40 negative (SV40-) and positive (SV40+)
- siFra-1 small interference RNA for Fra:
Expression vector for the small hairpin RNA directed towards Fra-1.
The authors acknowledge Drs. Maurizio Bocchetta and Amira Elmishad for their technical support in the immunohistochemistry of the CD44/SV40 tissue arrays. We also acknowledge Timothy Hunter, Scott Tighe, Mary Lou Shane, and Meghan Brown from the Vermont Cancer Center (VCC) DNA Analysis Facility at the University of Vermont for performing the Real Time-Quantitative PCR analysis. This research was supported by NCI grant K01 CA104159-01 (MERN) and PO1CA114047 (HP and BTM).
- Mossman B, Gee J: Asbestos related disease. N Engl J Med. 1989, 320: 1721-1730.View ArticlePubMedGoogle Scholar
- Mossman B, Bignon J, Corn M, Seaton A, Gee J: Asbestos: Scientific developments and implications for public policy. Science. 1990, 247: 294-301.View ArticlePubMedGoogle Scholar
- Carbone M, Rdzanek MA: Pathogenesis of malignant mesothelioma. Clin Lung Cancer. 2004, 5 (Suppl 2): S46-50.View ArticlePubMedGoogle Scholar
- Carbone M, Rizzo P, Pass H: Simian virus 40, polio vaccines and human tumors: a review of recent developments. Oncogene. 1997, 1877-1888.Google Scholar
- Comar M, Rizzardi C, de Zotti R, Melato M, Bovenzi M, Butel JS, Campello C: SV40 multiple tissue infection and asbestos exposure in a hyperendemic area for malignant mesothelioma. Cancer Res. 2007, 67: 8456-8459.View ArticlePubMedGoogle Scholar
- Kjaerheim K, Roe OD, Waterboer T, Sehr P, Rizk R, Dai HY, Sandeck H, Larsson E, Andersen A, Boffetta P, Pawlita M: Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples. Int J Cancer. 2007, 120: 2459-2465.View ArticlePubMedGoogle Scholar
- Ziegler A, Seemayer CA, Hinterberger M, Vogt P, Bigosch C, Gautschi O, Tornillo L, Betticher DC, Moch H, Stahel RA: Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results. Lung Cancer. 2007, 57: 282-291.View ArticlePubMedGoogle Scholar
- Mossman B, Gruenert D: SV40, growth factors, and mesothelioma – another piece of the puzzle. Am J Respir Cell Mol Biol. 2002, 26: 167-170.View ArticlePubMedGoogle Scholar
- Janssen Y, Heintz N, Mossman B: Induction of c-fos and c-jun proto-oncogene expression by asbestos is emeliorated by N-acetyl-L-cysteine in mesothelial cells. Cancer Res. 1995, 55: 2085-2089.PubMedGoogle Scholar
- Karin M, Liu A, Zandi E: AP-1 function and regulation. Curr Opin Cell Biol. 1997, 9: 240-246.View ArticlePubMedGoogle Scholar
- Reddy S, Mossman B: Role and regulaton of activator protein-1 in toxicant-induced responses of the lung. Am J Physiol (Lung Cell Mol Physiol). 2002, 283: L1161-L1178.View ArticleGoogle Scholar
- Heintz N, Janssen Y, Mossman B: Persistent induction of c-fos and c-jun expression by asbestos. Proc Natl Acad Sci USA. 1993, 90: 3299-3303.PubMed CentralView ArticlePubMedGoogle Scholar
- Zanella C, Posada J, Tritton T, Mossman B: Asbestos causes stimulation of the ERK-1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res. 1996, 56: 5334-5338.PubMedGoogle Scholar
- Shukla A, Flanders T, Lounsbury KM, Mossman BT: The gamma-glutamylcysteine synthetase and glutathione regulate asbestos-induced expression of activator protein-1 family members and activity. Cancer Res. 2004, 64: 7780-7786.View ArticlePubMedGoogle Scholar
- Ramos-Nino ME, Timblin CR, Mossman BT: Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res. 2002, 62: 6065-6069.PubMedGoogle Scholar
- Ramos-Nino ME, Scapoli L, Martinelli M, Land S, Mossman BT: Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. Cancer Res. 2003, 63: 3539-3545.PubMedGoogle Scholar
- Nagano O, Saya H: Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004, 95: 930-935.View ArticlePubMedGoogle Scholar
- Sneath RJ, Mangham DC: The normal structure and function of CD44 and its role in neoplasia. Mol Pathol. 1998, 51: 191-200.PubMed CentralView ArticlePubMedGoogle Scholar
- Bates RC, Edwards NS, Burns GF, Fisher DE: A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res. 2001, 61: 5275-5283.PubMedGoogle Scholar
- Weg-Remers S, Ponta H, Herrlich P, Konig H: Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J. 2001, 20: 4194-4203.PubMed CentralView ArticlePubMedGoogle Scholar
- Recio JA, Merlino G: Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1. Cancer Res. 2003, 63: 1576-1582.PubMedGoogle Scholar
- Penno MB, Askin FB, Ma H, Carbone M, Vargas MP, Pass HI: High CD44 expression on human mesotheliomas mediates association with hyaluronan. Cancer J Sci Am. 1995, 1: 196-203.PubMedGoogle Scholar
- Pettersson T, Froseth B, Riska H, Klockars M: Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest. 1988, 94: 1037-1039.View ArticlePubMedGoogle Scholar
- Thylen A, Hjerpe A, Martensson G: Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer. 2001, 92: 1224-1230.View ArticlePubMedGoogle Scholar
- Roboz J, Chahinian AP, Holland JF, Silides D, Szrajer L: Early diagnosis and monitoring of transplanted human malignant mesothelioma by serum hyaluronic acid. J Natl Cancer Inst. 1989, 81: 924-928.View ArticlePubMedGoogle Scholar
- Chiu B, Churg A, Tengblad A, Pearce R, McCaughey WT: Analysis of hyaluronic acid in the diagnosis of malignant mesothelioma. Cancer. 1984, 54: 2195-2199.View ArticlePubMedGoogle Scholar
- Afify AM, Stern R, Michael CW: Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol. 2005, 32: 145-150.View ArticlePubMedGoogle Scholar
- Nasreen N, Mohammed KA, Hardwick J, Van Horn RD, Sanders K, Kathuria H, Loghmani F, Antony VB: Low molecular weight hyaluronan induces malignant mesothelioma cell (MMC) proliferation and haptotaxis: role of CD44 receptor in MMC proliferation and haptotaxis. Oncol Res. 2002, 13: 71-78.PubMedGoogle Scholar
- Bourguignon LY, Zhu H, Shao L, Chen YW: CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J Biol Chem. 2000, 275: 1829-1838.View ArticlePubMedGoogle Scholar
- Matsui M, Tokuhara M, Konuma Y, Nomura N, Ishizaki R: Isolation of human fos-related genes and their expression during monocyte-macrophage differentiation. Oncogene. 1990, 5: 249-255.PubMedGoogle Scholar
- Hu Y, Lam K, Law S, Wong J, Srivastava G: Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin Cancer Res. 2001, 7: 2213-2221.PubMedGoogle Scholar
- Zajchowski D, Bartholdi M, Gong Y, Webster L, Liu H, Munishkin A, Beauheim C, Harvey S, Ethier S, Johnson P: Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res. 2001, 61: 5168-5178.PubMedGoogle Scholar
- Kim YH, Oh JH, Kim NH, Choi KM, Kim SJ, Baik SH, Choi DS, Lee ES: Fra-1 expression in malignant and benign thyroid tumor. Korean J Intern Med. 2001, 16: 93-97.PubMed CentralView ArticlePubMedGoogle Scholar
- Chiappetta G, Tallini G, De Biasio MC, Pentimalli F, de Nigris F, Losito S, Fedele M, Battista S, Verde P, Santoro M, Fusco A: FRA-1 expression in hyperplastic and neoplastic thyroid diseases. Clin Cancer Res. 2000, 6: 4300-4306.PubMedGoogle Scholar
- Belguise K, Kersual N, Galtier F, Chalbos D: FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene. 2005, 24: 1434-1444.View ArticlePubMedGoogle Scholar
- Cao H, Dronadula N, Rao GN: Thrombin induces expression of FGF-2 via activation of PI3K-Akt-Fra-1 signaling axis leading to DNA synthesis and motility in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2006, 290: C172-182.View ArticlePubMedGoogle Scholar
- Debinski W, Gibo DM: Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res. 2005, 3: 237-249.PubMedGoogle Scholar
- Ramos-Nino ME, Blumen SR, Sabo-Attwood T, Pass H, Carbone M, Testa J, Altomare DA, Mossman BT: HGF Mediates Cell Proliferation of Human Mesothelioma Cells Through a PI3K/MEK5/Fra-1 Pathway. Am J Respir Cell Mol Biol. 2007, [Epub ahead of print]Google Scholar
- Tiwari G, Sakaue H, Pollack JR, Roth RA: Gene expression profiling in prostate cancer cells with Akt activation reveals Fra-1 as an Akt-inducible gene. Mol Cancer Res. 2003, 1: 475-484.PubMedGoogle Scholar
- Tulchinsky E: Fos family members: regulation, structure and role in oncogenic transformation. Histol Histopathol. 2000, 15: 921-928.PubMedGoogle Scholar
- Vallone D, Battista S, Pierantoni G, Fedele M, Casalino L, Santoro M, Viglietto G, Fusco A, Verde P: Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product. EMBO J. 1997, 16: 5310-5321.PubMed CentralView ArticlePubMedGoogle Scholar
- Yang HS, Knies JL, Stark C, Colburn NH: Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene. 2003, 22: 3712-3720.View ArticlePubMedGoogle Scholar
- Zhang Q, Adiseshaiah P, Kalvakolanu DV, Reddy SP: A phosphatidylinositol 3-kinase regulated Akt independent signaling promotes cigarette smoke induced FRA-1 expression. J Biol Chem. 2006, 281: 10174-10181.View ArticlePubMedGoogle Scholar
- Scapoli L, Ramos-Nino M, Martinelli M, Mossman B: Src-dependent ERK5 and Src/EGFR-dependent ERK1/2 activation is required for cell proliferation by asbestos. Oncogene. 2004, 23: 805-813.View ArticlePubMedGoogle Scholar
- Zhang Q, Adiseshaiah P, Reddy SP: Matrix metalloproteinase/epidermal growth factor receptor/mitogen-activated protein kinase signaling regulate fra-1 induction by cigarette smoke in lung epithelial cells. Am J Respir Cell Mol Biol. 2005, 32: 72-81.View ArticlePubMedGoogle Scholar
- Lamb R, Hennigan R, Turnbull K, Katsanakis K, MacKenzie E, Birnie G, Ozanne B: AP-1 mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol Cell Biol. 1997, 17: 963-976.PubMed CentralView ArticlePubMedGoogle Scholar
- Song Y, Song S, Zhang D, Zhang Y, Chen L, Qian L, Shi M, Zhao H, Jiang Z, Guo N: An association of a simultaneous nuclear and cytoplasmic localization of Fra-1 with breast malignancy. BMC Cancer. 2006, 6: 298-PubMed CentralView ArticlePubMedGoogle Scholar
- Yu Y, Alwine JC: Human cytomegalovirus major immediate-early proteins and simian virus 40 large T antigen can inhibit apoptosis through activation of the phosphatidylinositide 3'-OH kinase pathway and the cellular kinase Akt. J Virol. 2002, 76: 3731-3738.PubMed CentralView ArticlePubMedGoogle Scholar
- Yuan H, Veldman T, Rundell K, Schlegel R: Simian virus 40 small tumor antigen activates AKT and telomerase and induces anchorage-independent growth of human epithelial cells. J Virol. 2002, 76: 10685-10691.PubMed CentralView ArticlePubMedGoogle Scholar
- Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, Jhanwar SC, Mossman BT, Kane AB, Testa JR: Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. 2005, 24: 6080-6089.View ArticlePubMedGoogle Scholar
- Ramos-Nino ME, Vianale G, Sabo-Attwood T, Mutti L, Porta C, Heintz N, Mossman BT: Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. Mol Cancer Ther. 2005, 4: 835-842.View ArticlePubMedGoogle Scholar
- Fulgenzi G, Graciotti L, Faronato M, Soldovieri MV, Miceli F, Amoroso S, Annunziato L, Procopio A, Taglialatela M: Human neoplastic mesothelial cells express voltage-gated sodium channels involved in cell motility. Int J Biochem Cell Biol. 2006, 38: 1146-1159.View ArticlePubMedGoogle Scholar
- Nasreen N, Mohammed KA, Antony VB: Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer. 2006, 107: 2425-2435.View ArticlePubMedGoogle Scholar
- Giuffrida A, Scarpa S, Birarelli P, Modesti A: The interaction of tenascin-C with fibronectin modulates the migration and specific metalloprotease activity in human mesothelioma cell lines of different histotype. Int J Oncol. 2004, 25: 745-750.PubMedGoogle Scholar
- Kroczynska B, Cutrone R, Bocchetta M, Yang H, Elmishad AG, Vacek P, Ramos-Nino M, Mossman BT, Pass HI, Carbone M: Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA. 2006, 103: 14128-14133.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu Z, Klominek J: Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors. Neoplasia. 2004, 6: 705-712.PubMed CentralView ArticlePubMedGoogle Scholar
- Klominek J, Sumitran Karuppan S, Hauzenberger D: Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: the role of beta1 integrins. Int J Cancer. 1997, 72: 1034-1044.View ArticlePubMedGoogle Scholar
- Testa J, Carbone M, Hirvonen A, Khalili K, Krynska B, Linnainmaa K, Pooley F, Rizzo P, Rusch V, Xiao G: A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. Cancer Res. 1998, 58: 4505-4509.PubMedGoogle Scholar
- Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR: Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA. 2001, 98: 247-252.PubMed CentralView ArticlePubMedGoogle Scholar
- Luo Y, Prestwich GD: Hyaluronic acid-N-hydroxysuccinimide: a useful intermediate for bioconjugation. Bioconjug Chem. 2001, 12: 1085-1088.View ArticlePubMedGoogle Scholar
- Carbone M, Rdzanek MA, Rudzinski JJ, De Marco MA, Bocchetta M, Ramos Nino M, Mossman B, Pass HI: SV40 detection in human tumor specimens. Cancer Res. 2005, 65: 10120-10121.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.